FUS

Chr 16AD

FUS RNA binding protein

Also known as: ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS, altFUS

This gene encodes a multifunctional protein component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex. The hnRNP complex is involved in pre-mRNA splicing and the export of fully processed mRNA to the cytoplasm. This protein belongs to the FET family of RNA-binding proteins which have been implicated in cellular processes that include regulation of gene expression, maintenance of genomic integrity and mRNA/microRNA processing. Alternative splicing results in multiple transcript variants. Defects in this gene result in amyotrophic lateral sclerosis type 6. [provided by RefSeq, Sep 2009]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismADLOEUF 0.242 OMIM phenotypes
Clinical SummaryFUS
🧬
Gene-Disease Validity (ClinGen)
amyotrophic lateral sclerosis type 6 · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
51 unique Pathogenic / Likely Pathogenic· 284 VUS of 686 total submissions
💊
Clinical Trials
6 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — FUS
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.24LOEUF
pLI 0.999
Z-score 5.16
OE 0.10 (0.050.24)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
2.21Z-score
OE missense 0.66 (0.590.74)
217 obs / 329.7 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?
LoF OE?0.10 (0.050.24)
00.351.4
Missense OE?0.66 (0.590.74)
00.61.4
Synonymous OE?1.25
01.21.6
LoF obs/exp: 4 / 38.6Missense obs/exp: 217 / 329.7Syn Z: -2.13

This gene — mechanism propensity

DN
0.4686th %ile
GOF
0.3392th %ile
LOF
0.79top 5%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to loss-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · 57% of P/LP variants are LoF · LOEUF 0.24
GOF1 literature citation

Literature Evidence

GOFThe implications of this would be a progressive generalized disruption to transcription and RNA processing, and suggests a mechanism by which C-terminal FUS/TLS mutations may exert their effects by a toxic gain of function.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 20385912

ClinVar Variant Classifications

686 submitted variants in ClinVar

Classification Summary

Pathogenic31
Likely Pathogenic20
VUS284
Likely Benign215
Benign47
Conflicting39
31
Pathogenic
20
Likely Pathogenic
284
VUS
215
Likely Benign
47
Benign
39
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
18
13
0
0
31
Likely Pathogenic
11
9
0
0
20
VUS
5
176
100
3
284
Likely Benign
1
11
119
84
215
Benign
0
1
42
4
47
Conflicting
39
Total3521026191636

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

11 pathogenic / likely-pathogenic (of 20) ClinVar copy-number / structural variants overlap FUS — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

FUS · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Amyotrophic Lateral Sclerosis (ALS)

Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations

NOT YET RECRUITING
NCT07080801Phase EARLY_PHASE1Beijing Tiantan HospitalStarted 2025-08
RAG-21
ALS

Amyotrophic Lateral Sclerosis (ALS) Families Project

RECRUITING
NCT03865420Columbia UniversityStarted 2018-09-11
Amyotrophic Lateral Sclerosis

Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS

RECRUITING
NCT05747937Phase NAIstituti Clinici Scientifici Maugeri SpAStarted 2021-05-15
Skin biopsyCardiovascular Reflexes testingAdministration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Neurodegenerative DiseaseBehavioral Variant Frontotemporal Dementia (bvFTD)Primary Progressive Aphasia(PPA)

Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases

ENROLLING BY INVITATION
NCT07567664Phase NAIRCCS San RaffaeleStarted 2017-06-01
3 Tesla MRI without contrast mediumBlood sample for genetic analysisCerebrospinal fluid sampling (CSF)
Amyotrophic Lateral Sclerosis

Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis

RECRUITING
NCT06083584Centre Hospitalier Universitaire de NīmesStarted 2023-11-22
RNA sequencing
Brain NeoplasmsLiquid Biopsy

BRAINFUL (BRAIN Tumor Focused Ultrasound-enabled Liquid Biopsy) Trial

ACTIVE NOT RECRUITING
NCT04940507Phase NAUniversity Health Network, TorontoStarted 2021-06-10
Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy AcquisitionMagnetic Resonance Guided Focused Ultrasound Thalamotomy